TARRYTOWN, N.Y., Oct. 14, 2011 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. Chief Executive Officer Mark R. Baker will present at the 18th Annual "NewsMakers in the Biotech Industry" conference sponsored by BioCentury and Thomson Reuters on Friday, October 21st in New York City. The 3:00 p.m. Eastern time presentation will be webcast live on the Events page of Progenics' website and remain available for 30 days.
Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) develops innovative therapeutics for patients suffering from cancer and related conditions. Its pipeline candidates include PSMA ADC, a human monoclonal antibody-drug conjugate in phase 1 clinical testing for treatment of prostate cancer, and preclinical stage novel multiplex phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer. Progenics' first commercial product, RELISTOR® (methylnaltrexone bromide) Subcutaneous Injection, is a first-in-class treatment for opioid-induced constipation. It is approved in over 50 countries for patients with advanced illness and licensed to Salix Pharmaceuticals, Ltd. for markets worldwide other than Japan, where Ono Pharmaceutical Co., Ltd. is developing the subcutaneous formulation. A U.S. application for approval of RELISTOR to treat OIC in patients with chronic, non-cancer pain is pending; and a phase 3 clinical trial of an oral formulation of methylnaltrexone in this patient population completed enrollment in mid-2011.
The Progenics Pharmaceuticals, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=9678
Additional information concerning Progenics and its business may be available in press releases or other announcements and public filings made after this release.
(PGNX-G)
Editors Note:
For more information, please visit www.progenics.com.